Zhejiang Garden Biopharmaceutical Co.,Ltd.

XSEC:300401 Stock Report

Market Cap: CN¥8.1b

Zhejiang Garden BiopharmaceuticalLtd Past Earnings Performance

Past criteria checks 3/6

Zhejiang Garden BiopharmaceuticalLtd's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13.2% per year. Zhejiang Garden BiopharmaceuticalLtd's return on equity is 9.1%, and it has net margins of 25.1%.

Key information

-6.3%

Earnings growth rate

-9.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate13.2%
Return on equity9.1%
Net Margin25.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Garden BiopharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300401 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,13428529891
30 Jun 241,03821730490
31 Mar 241,10823234995
31 Dec 231,09519237691
30 Sep 231,23717943787
30 Jun 231,27420446683
31 Mar 231,34828446670
01 Jan 231,41838444770
30 Sep 221,42746642866
30 Jun 221,38546141463
31 Mar 221,32954333869
01 Jan 221,11748425859
30 Sep 2193740919258
30 Jun 2184742011753
31 Mar 216992939744
31 Dec 206592639345
30 Sep 206302617135
30 Jun 206452777138
31 Mar 206172767042
31 Dec 197183446843
30 Sep 197633927147
30 Jun 197583847644
31 Mar 196613157436
01 Jan 196603076831
30 Sep 185852525732
30 Jun 185082084731
31 Mar 185692324925
01 Jan 184201305322
30 Sep 17416120626
30 Jun 17403103620
31 Mar 1735560720
31 Dec 1632944680
30 Sep 1627229580
30 Jun 1623917620
31 Mar 1617810470
31 Dec 1515112480
30 Sep 1515222510
30 Jun 1515833470
31 Mar 1516338500
31 Dec 1415937490
30 Sep 1415840490
31 Dec 1318436450

Quality Earnings: 300401 has a large one-off gain of CN¥86.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300401's current net profit margins (25.1%) are higher than last year (14.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300401's earnings have declined by 6.3% per year over the past 5 years.

Accelerating Growth: 300401's earnings growth over the past year (59.3%) exceeds its 5-year average (-6.3% per year).

Earnings vs Industry: 300401 earnings growth over the past year (59.3%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 300401's Return on Equity (9.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:38
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Garden Biopharmaceutical Co.,Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhe WangCitic Securities Co., Ltd.
Wei LiuHaitong International Research Limited
Song YangTianfeng Securities Brokerage Co., Ltd